Stay updated with breaking news from Oche. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Roche is acquiring global rights to a Zion Pharma Limited drug candidate with potential applications treating breast cancer that has metastasized to the brain. The small molecule, currently in Phase 1 testing, is designed to penetrate the blood-brain barrier.
Chemed Co. (NYSE:CHE – Get Rating) CEO Kevin J. Mcnamara sold 4,000 shares of the stock in a transaction on Friday, May 5th. The stock was sold at an average price of $549.34, for a total transaction of $2,197,360.00. Following the transaction, the chief executive officer now directly owns 119,571 shares in the company, valued […]
Boston Partners lifted its stake in Chemed Co. (NYSE:CHE – Get Rating) by 0.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 24,514 shares of the company’s stock after buying an additional 57 shares during the period. Boston Partners owned […]
Oppenheimer & Co. Inc. lessened its holdings in shares of Chemed Co. (NYSE:CHE – Get Rating) by 2.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,507 shares of the company’s stock after selling 436 shares during the quarter. Oppenheimer & Co. […]
Oppenheimer & Co. Inc. cut its holdings in shares of Chemed Co. (NYSE:CHE – Get Rating) by 2.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 14,507 shares of the company’s stock after selling 436 shares during the quarter. Oppenheimer & Co. Inc.’s holdings […]